Safety of giving an RSV preventive antibody with routine childhood vaccines
Safety of Simultaneous Administration of Respiratory Syncytial Virus (RSV) Preventive Monoclonal Antibody With Routine Childhood Immunizations in Infants
This trial will test whether giving an RSV preventive antibody at the same visit as routine childhood vaccines is as safe for infants 6 to <30 weeks old as giving the antibody at a separate visit.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 524 (estimated) |
| Ages | 6 Weeks to 30 Weeks |
| Sex | All |
| Sponsor | Duke University Academic / other |
| Drugs / interventions | chemotherapy, radiation, prednisone |
| Locations | 6 sites (Oakland, California and 5 other locations) |
| Trial ID | NCT07158814 on ClinicalTrials.gov |
What this trial studies
This is a prospective, randomized, open-label trial comparing simultaneous administration of an RSV preventive monoclonal antibody with routine childhood vaccines at one visit versus giving the antibody and vaccines at separate visits. Parents or guardians will record fever and other solicited local and systemic adverse events on the day of immunization and for the next six days after each vaccination visit using a web-based system or paper memory aid. Serious adverse events and adverse events of special interest will be collected throughout the study period. The trial is conducted at multiple U.S. clinical sites and enrolls infants aged 6 weeks to under 30 weeks who are eligible for the RSV antibody and routine vaccines.
Who should consider this trial
Good fit: Infants aged 6 weeks to under 30 weeks who are eligible for the RSV monoclonal antibody and at least one routine childhood vaccine, whose parent or legal guardian can consent, read English or Spanish, and attend follow-up, are ideal candidates.
Not a fit: Infants outside the 6 to <30-week age range, those not eligible for the RSV antibody or routine vaccines, or families unable to comply with consent and follow-up requirements are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the results could allow infants to receive the RSV antibody at the same visit as routine vaccines without increased short-term side effects, reducing clinic visits and scheduling burden for families.
How similar studies have performed: Previous clinical and postmarketing work has established safety profiles for RSV monoclonal antibodies in infants, but randomized comparisons of simultaneous versus sequential administration with routine vaccines are limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Infants ≥ 6 weeks to \<30 weeks of age at the time of enrollment * Infants eligible for RSV monoclonal antibody and at least one routine childhood vaccine in outpatient clinic * The parent/legal guardian must be willing and capable of providing permission for their infant to participate through the written informed consent process * Parent/legal guardian must be able to read and comprehend English or Spanish * The parent/legal guardian must be available for follow-up study contact by telephone from enrollment to completion of the study period * The parent/legal guardian must agree to sign a medical record release for the infant so that study personnel may obtain medical information about the infant's health (if needed) * The parent/legal guardian must be willing to delay their child's receipt of RSV monoclonal antibody up to two weeks from the scheduled date and to return for a second visit to receive the deferred RSV monoclonal antibody Exclusion Criteria: * Known contraindication or precaution to RSV monoclonal antibody or other routine vaccines being administered * Received any vaccine within 14 days prior to enrollment and the first immunization day in this study * Known previous receipt of RSV monoclonal antibody * Received any experimental/investigational agent (vaccine, drug, biologic, device, blood product, or medication) within 28 days prior to immunization in this study or expects to receive an experimental/investigational agent within the follow-up time period (8 days after the second immunization in this study) * A moderate to severe acute illness and/or a reported temporal temperature greater than or equal to 100.4°F (38.0°C) within 48 hours prior to enrollment or a temporal temperature (measured by temporal artery thermometer) greater than or equal to 100.4°F (38.0°C) at the time of enrollment. (This may result in a temporary delay of immunization) * Receipt of an antipyretic medication (acetaminophen or ibuprofen) within 48 hours prior to enrollment (This may result in a temporary delay of immunization) * Planned receipt of a prophylactic antipyretic medication on the day of and/or days following immunization. This exclusion does not apply if the parent/legal guardian indicates they might administer antipyretics after immunization in response to fever or pain * Has any condition that would, in the opinion of the site investigator, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol * Anyone who is a first-degree relative of any research study personnel * The infant is born to a mother who received a maternal RSV immunization more than 14 days prior to delivery and is not eligible for RSV preventative monoclonal antibody * Bleeding disorder or condition associated with prolonged bleeding that would present as a safety risk per opinion of the investigator * History of severe adverse reaction associated with a vaccine and/or severe allergic reaction to any component of the vaccines or RSV monoclonal antibody * Has an active neoplastic disease, or a history of any hematologic malignancy * History of a severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of a vaccine administered on the day of study enrollment * Immunosuppression as a result of an underlying illness or treatment or use of anti-cancer chemotherapy or radiation therapy since birth * For infants receiving DTaP vaccine (alone or combination vaccine): Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures), not attributable to another identifiable cause, within 7 days of administration of previous dose of DTaP * Intention to receive non-live or live vaccines during the 4 weeks after Visit 1; vaccines may be administered after enrollment if deemed a personal or public health priority by the health care provider caring for this patient or the study team * Long term (at least 14 days of prednisone 2 mg/kg/day or equivalent other glucocorticoid) use of any parenteral steroids within the 6 months prior to enrollment (topical, nasal and inhaled steroids are allowed)
Where this trial is running
Oakland, California and 5 other locations
- Kaiser Permanente Northern California — Oakland, California, United States (Recruiting)
- Emory University — Atlanta, Georgia, United States (Recruiting)
- Centers for Disease Control and Prevention — Atlanta, Georgia, United States (Active_not_recruiting)
- Columbia University — New York, New York, United States (Recruiting)
- Duke University — Durham, North Carolina, United States (Recruiting)
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States (Recruiting)
Study contacts
- Principal investigator: Michael J Smith, MD — Duke University
- Study coordinator: Michael J Smith, MD
- Email: michael.j.smith@duke.edu
- Phone: 919 684 6335
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.